Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

Noncovalent Bruton tyrosine kinase inhibitors like pirtobrutinib may be a more effective first-line therapy for chronic ...

Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...

ORLANDO -- In a phase III trial with potential practice-changing implications, the non-covalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) induced a higher response rate in ...

美国FDA于2025年12月3日批准了礼来公司的Jaypirca（pirtobrutinib，匹妥布替尼）扩大适应症，用于治疗既往接受过共价BTK抑制剂治疗的复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（CLL/SLL）成人患者。此次批准将于20 ...

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval to ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...

默沙东致力于推动血液肿瘤领域的创新与患者关怀。基于肿瘤领域的前沿探索，公司已建立了广泛的临床开发项目，评估多种新型作用机制，力求解决血液肿瘤患者长期未满足的治疗需求。默沙东的研究涵盖多款在研药物，单药或联合其他疗法，覆盖多种血液肿瘤类型。